Effects of levosimendan on myocardial infarct size and hemodynamics in a closed-chest porcine ischemia-reperfusion model

Cardiovascular Drugs and Therapy

Volumn 20, Issue 5, 2006, Pages 335-342

  Busk, Martin ^a   Maeng, Michael ^a   Kristensen, Jens ^a   Berg, Jette Scheby ^a   Mortensen, Ulrik Markus ^a   Nielsen, Torsten Toftegaard ^a   Nielsen Kudsk, Jens Erik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Calcium sensitizers; Experimental AMI; Hemodynamics; Myocardial infarct size

Indexed keywords

FLUORESCEIN; LEVOSIMENDAN; SODIUM CHLORIDE; TETRAZOLIUM;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY OCCLUSION; ARTICLE; BALLOON OCCLUSION; BIOLOGICAL MONITORING; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY COLLATERAL CIRCULATION; DRUG EFFECT; DRUG INFUSION; EX VIVO STUDY; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE REPERFUSION; HEART OUTPUT; HEART VENTRICLE CONTRACTION; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HISTOPATHOLOGY; IMAGING; IN VIVO STUDY; LEFT CORONARY ARTERY; LOADING DRUG DOSE; LUNG CAPILLARY PRESSURE; MANOMETER; NONHUMAN; OBSERVATION; PRIORITY JOURNAL; REPERFUSION; STAINING; STATISTICAL SIGNIFICANCE; SWAN GANZ CATHETER; SWINE;

ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT; CARDIOTONIC AGENTS; FEMALE; HEART VENTRICLES; HYDRAZONES; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PYRIDAZINES; SWINE; VASODILATOR AGENTS;

EID: 33845641680     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-006-0294-0     Document Type: Article

References (38)

1. du Toit EF, Muller CA, McCarthy J, Opie LH. Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 1999;290:505-14.
2. Kersten JR, Montgomery MW, Pagel PS, Warltier DC. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000;90:5-11.
3. Levijoki J, Pollesello P, Kaheinen P, Haikala H. Improved survival with simendan after experimental myocardial infarction in rats. Eur J Pharmacol 2001;419:243-8.
4. Rump AF, Acar D, Rosen R, Klaus W. Functional and antiischaemic effects of the phosphodiesterase inhibitor levosimendan in isolated rabbit hearts. Pharmacol Toxicol 1994;74:244-8.
5. MacGowan GA. The myofilament force-calcium relationship as a target for positive inotropic therapy in congestive heart failure. Cardiovasc Drugs Ther 2005;19:203-10.
6. Nielsen-Kudsk JE, Aldershvile J. Will calcium sensitizers play a role in the treatment of heart failure? J Cardiovasc Pharmacol 1995;26(Suppl 1):S77-84.
7. Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144:1102-8.
8. David S, Zaks JM. Arrhythmias associated with intermittent outpatient dobutamine infusion. Angiology 1986;37:86-91.
9. Krell MJ, Kline EM, Bates ER, Hodgson JM, Dilworth LR, Laufer N, et al. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Am Heart J 1986;112:787-91.
10. Schulz R, Rose J, Martin C, Brodde OE, Heusch G. Development of short-term myocardial hibernation. Its limitation by the severity of ischemia and inotropic stimulation. Circulation 1993;88:684-95.
11. Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998;19:660-8.
12. Singh BN, Lilleberg J, Sandell EP, Ylonen V, Lehtonen L, Toivonen L. Effects of levosimendan on cardiac arrhythmia: electrophysiological and ambulatory findings in phase II and III clinical studies in cardiac failure. Am J Cardiol 1999;83:16(I)-20(I).
13. Michaels AD, McKeown B, Kostal M, Vakharia KT, Jordan MV, Gerber IL, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005;111:1504-9.
14. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004;43:2177-82.
15. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002;23:1422-32.
16. Cleland JG, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004;6:501-8.
17. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006;8:105-10.
18. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
19. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther 1997;283:375-83.
20. Ozdem SS, Yalcin O, Meiselman HJ, Baskurt OK, Usta C. The role of potassium channels in relaxant effect of levosimendan in rat small mesenteric arteries. Cardiovasc Drugs Ther 2006.
21. Yokoshiki H, Sperelakis N. Vasodilating mechanisms of levosimendan. Cardiovasc Drugs Ther 2003;17:111-13.
22. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, Bang L, Olesen SP, Aldershvile J. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998;31:741-9.
23. Pataricza J, Krassoi I, Hohn J, Kun A, Papp JG. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 2003;17:115-21.
24. Galie N, Guarnieri C, Ussia GP, Zimarino M., Traini AM, Parlangeli R, et al. Limitation of myocardial infarct size by nicorandil after sustained ischemia in pigs. J Cardiovasc Pharmacol 1995;26:477-84.
25. Yao Z, Gross GJ. Effects of the KATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation 1994;89:1769-75.
26. White FC, Bloor CM. Coronary collateral circulation in the pig: correlation of flow with coronary bed size. Basic Res Cardiol 1981;76:189-96.
27. Tassani P, Schad H, Heimisch W, Bernhard-Abt A, Ettner U, Mendler N, et al. Effect of the calcium sensitizer levosimendan on the performance of ischaemic myocardium in anaesthetised pigs. Cardiovasc Drugs Ther 2002;16:435-41.
28. Kristensen J, Mortensen U, Nielsen SS, Maeng M, Nielsen TT, Rehling M. Ischaemic preconditioning in the pig assessed by myocardial perfusion imaging and histochemistry. APMIS Suppl 2003;122-6.
29. Ravn HB, Moeldrup U, Brookes CI, Ilkjaer LB, White P, Chew M, et al. Intravenous magnesium reduces infarct size after ischemia/reperfusion injury combined with a thrombogenic lesion in the left anterior descending artery. Arterioscler Thromb Vasc Biol 1999;19:569-74.
30. Kristensen J, Mortensen UM, Nielsen SS, Maeng M, Kaltoft A, Nielsen TT, et al. Myocardial perfusion imaging with 99mTc sestamibi early after reperfusion reliably reflects infarct size reduction by ischaemic preconditioning in an experimental porcine model. Nucl Med Commun 2004;25:495-500.
31. Schwartz LM, Verbinski SG, Vander Heide RS, Reimer KA. Epicardial temperature is a major predictor of myocardial infarct size in dogs. J Mol Cell Cardiol 1997;29:1577-83.
32. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-12.
33. Trines SA, Smits CA, van der MJ, Slager CJ, Verdouw PD, Krams R. Calcium sensitizer EMD 57033, but not the beta1-adrenoreceptor agonist dobutamine, increases mechanical efficiency in stunned myocardium. J Cardiovasc Pharmacol 2002;39:61-72.
34. Hasenfuss G, Mulieri LA, Allen PD, Just H, Alpert NR. Influence of isoproterenol and ouabain on excitation-contraction coupling, cross-bridge function, and energetics in failing human myocardium. Circulation 1996;94:3155-60.
35. du Toit EF, Hofmann D, McCarthy J, Pineda C. Effect of levosimendan on myocardial contractility, coronary and peripheral blood flow, and arrhythmias during coronary artery ligation and reperfusion in the in vivo pig model. Heart 2001;86:81-7.
36. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study investigators. Circulation 2000;102:2222-7.
37. Edes I, Kiss E, Kitada Y, Powers FM, Papp JG, Kranias EG, et al. Effects of Levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995;77:107-13.
38. Sato S, Talukder MA, Sugawara H, Sawada H, Endoh M. Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit. J Mol Cell Cardiol 1998;30:1115-28.